Printer Friendly

ROYCE LABORATORIES RECEIVES FDA APPROVAL FOR LORAZEPAM IN THREE DOSAGE STRENGTHS

             ROYCE LABORATORIES RECEIVES FDA APPROVAL FOR
                  LORAZEPAM IN THREE DOSAGE STRENGTHS
    MIAMI, Nov. 1 /PRNewswire/ -- Royce Laboratories, Inc. (NASDAQ: RLAB) today announced that it has received approval from the Food and Drug Administration for Lorazepam in three dosage strengths (0.5 mg, 1.0 mg, and 2.0 mg).
    Lorazepam is the generic equivalent of Ativan, a tranquilizer manufactured by Wyeth Laboratories.
    This is the fifth ANDA (Abbreviated New Drug Application) approval that Royce has received in the last seven months, and at the present time Royce has an additional six drugs in various dosage strengths pending with the FDA.
    Royce Laboratories, Inc. is a manufacturer of prescription and over-the-counter generic pharmaceuticals.
    -0-                        11/1/91
    /CONTACT:  Patrick J. McEnany, president of Royce Laboratories, Inc., 305-624-1500/
    (RLAB) CO:  Royce Laboratories, Inc. ST:  Florida IN:  MTC SU: AW-MR -- FL003 -- 0084 11/01/91 09:03 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1991
Words:145
Previous Article:WESTERN ENERGY INC. ISSUES STATEMENT TO SHAREHOLDERS
Next Article:THERAGENICS RECORDS THIRD CONSECUTIVE PROFITABLE QUARTER; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS REVENUE 120 PERCENT
Topics:


Related Articles
ROYCE LABORATORIES FILES FOR $6 MILLION SECONDARY PUBLIC OFFERING
ROYCE LABORATORIES, INC. HAS FILED APPLICATIONS (ANDAs) FOR THREE NEW PRODUCTS
ROYCE LABORATORIES, INC. RECEIVES FDA APPROVALS FOR BACLOFEN
ROYCE LABORATORIES, INC. RECEIVES FDA APPROVALS FOR HYDROXYZINE HYDROCLORIDE
ROYCE LABORATORIES, INC. RECEIVES FDA APPROVAL FOR CYCLOBENZAPRINE HYDROCHLORIDE
ROYCE LABORATORIES, INC. RECEIVES FDA APPROVAL FOR ACETAMINOPHEN WITH CODEINE
ROYCE LABORATORIES, INC. FILES PETITION SEEKING REVIEW OF FDA DECISION TO DELAY APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR CAPTOPRIL PENDING...
ROYCE LABORATORIES, INC. RECEIVES FDA APPROVAL FOR PIROXICAM
ROYCE LABORATORIES, INC. ANNOUNCES FDA FINAL APPROVAL FOR CAPTOPRIL
ROYCE LABORATORIES, INC. ANNOUNCES FDA APPROVAL FOR SIX DOSAGE STRENGTHS OF HYDROCODONE BITARTRATE/ACETAMINOPHEN

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters